Tempus has been one of the top topics in the conversations about the need to successfully merge technology innovation outside the cancer research world with actual cancer research and treatment. The company was founded by Eric Lefkofsky and has already done incredibly things to move the process of data-driven cancer treatment forward.
The goal of Tempus is to create the world’s largest library of molecular and clinical data housed within a system that is readily accessible to physicians and is able to be used in an effective way to treat cancer patients. Tempus will collect data from physicians on individual patients and pair that with molecular data gathered from a process called human genome sequencing to help move this data driven approach forward in the world of cancer treatment and other diseases and more information click here.
If you are not familiar with Eric Lefkofsky, he is a well-known tech entrepreneur that has made many successful ventures, the most popular being when he co-founded Groupon. Lefkofsky was born in Michigan and earned a law degree from the University of Michigan before realizing his passion for teach and foregoing law to pursue ventures in the dot-com world.
When his wife was diagnosed with breast cancer, he noticed something that struck him as very odd in the treatment process. At every point of a patient’s care and treatment, data is collected. Yet, he asked himself ‘where does that data go?’ ‘how is it being utilized?’ The answer was that it wasn’t being utilized to the full capacity. There was a mountain of data, much collected simply through physician notes, and it was being stored with patient files within that one hospital or facility.
Lefkofsky founded Tempus to rectify that issue. Tempus harnessed the power of technology and digital platforms to read physician data and then to translate it into useable data that can be accessed in an efficient way. On top of physician data, Tempus is seeking to add molecular data unearthed from human genome process to create a deeper layer of understanding behind an individual patient’s experience with cancer. It is the hope that these two layers combined will paint a better picture of the best treatment for patients in the future.